KR20090088205A - Composition of biji fermentation products with lactobacillus acidophillus on the prevention of menopausal obesity - Google Patents
Composition of biji fermentation products with lactobacillus acidophillus on the prevention of menopausal obesity Download PDFInfo
- Publication number
- KR20090088205A KR20090088205A KR1020080013606A KR20080013606A KR20090088205A KR 20090088205 A KR20090088205 A KR 20090088205A KR 1020080013606 A KR1020080013606 A KR 1020080013606A KR 20080013606 A KR20080013606 A KR 20080013606A KR 20090088205 A KR20090088205 A KR 20090088205A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- lactic acid
- acid fermentation
- lactobacillus
- preventing
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09F—DISPLAYING; ADVERTISING; SIGNS; LABELS OR NAME-PLATES; SEALS
- G09F15/00—Boards, hoardings, pillars, or like structures for notices, placards, posters, or the like
- G09F15/0006—Boards, hoardings, pillars, or like structures for notices, placards, posters, or the like planar structures comprising one or more panels
- G09F15/0012—Boards, hoardings, pillars, or like structures for notices, placards, posters, or the like planar structures comprising one or more panels frames therefor
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09F—DISPLAYING; ADVERTISING; SIGNS; LABELS OR NAME-PLATES; SEALS
- G09F13/00—Illuminated signs; Luminous advertising
- G09F13/04—Signs, boards or panels, illuminated from behind the insignia
- G09F13/0413—Frames or casing structures therefor
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09F—DISPLAYING; ADVERTISING; SIGNS; LABELS OR NAME-PLATES; SEALS
- G09F13/00—Illuminated signs; Luminous advertising
- G09F13/04—Signs, boards or panels, illuminated from behind the insignia
- G09F13/0418—Constructional details
- G09F13/0445—Frames
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09F—DISPLAYING; ADVERTISING; SIGNS; LABELS OR NAME-PLATES; SEALS
- G09F15/00—Boards, hoardings, pillars, or like structures for notices, placards, posters, or the like
- G09F15/0006—Boards, hoardings, pillars, or like structures for notices, placards, posters, or the like planar structures comprising one or more panels
- G09F15/0018—Boards, hoardings, pillars, or like structures for notices, placards, posters, or the like planar structures comprising one or more panels panel clamping or fastening means
Landscapes
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Theoretical Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 젖산발효 비지로부터 유래한 비지 발효물의 갱년기 여성 비만 방지, 골다공증 및/또는 고지혈증 등의 예방 및 치료용 조성물에 관한 것이다.The present invention relates to compositions for preventing and treating obesity, women's obesity prevention, osteoporosis and / or hyperlipidemia, such as fermentation of a busy fermentation derived from lactic acid fermentation.
두부로부터 얻어지는 비지는 수분함량이 ８１％ 정도이며 일반성분은 건물량을 기준으로 할 때， 단백질이 ２４％， 지방이 １５％， 탄수화물이 ５５％， 회분이 ４％ 및 조섬유가 １４％이다． 이소플라본 함량이 지금까지도 콩가공 부산물인 비지를 식품가공소재로 비지를 활용하기 위해 비지의 부산물에 대한 pH, 아미노산 함량 및 당 함량 등을 중심으로 비지의 영양성 및 기호성을 증진시키기 위한 연구가 보고 된 바 있다．The tofu obtained from tofu contains about 1% water content, and the general composition is 24% protein, 15% fat, 45% carbohydrate, 4% ash and 14% crude fiber, based on dry matter. So far, Isoflavones have been reported to improve the nutritional and symbolic properties of soybeans by focusing on the pH, amino acid content and sugar content of by-products in order to utilize them as food processing materials. It is changed.
최근 인구의 고령화 및 건강에 대한 의식이 높아짐에 따라 두류의 갱년기 여성 장애 예방 작용을 갖는 기능성 물질에 관심이 집중되고 있다． 특히 여성에 있어서 폐경기에 이른 중년 여성의 폐경기로 인한 비만 및 골다공증의 발증은 삶의 질에 크게 영향을 미칠 뿐만이 아니라 국가적인 의료비의 부담이 크게 늘어날 소지가 큰 것으로 알려져 있다． 이같이 사회적인 관심의 대상이 되고 있는 폐경기 전후의 질병에 대한 예방책으로서 콩에 들어있는 이소플라본 중 특히 이소플라본 아글리콘이 매우 유효한 것으로 알려지고 있다（Masayoshi Yamaguchi, 2006, Yakugaku Zasshi, 126(11) 1117-1137, ). 대두는 양질의 식물성 단백질원으로 두부 등의 제조에 널리 이용되어 왔으며 최근에는 대두에 함유되어 있는 각종 기능성 및 생리활성 물질들 중 이소플라본이 보고되면서 기능성 건강 식품의 소재로서 다양하게 활용되고 있다 （Knight DC et al, 1996, Obest. Gynecol, 87, 897-904).Recently, with the aging of the population and the growing awareness of health, attention has been focused on functional substances that have preventive effects on menopausal women. In particular, the onset of obesity and osteoporosis due to menopause in middle-aged women who have reached menopause, not only significantly affects the quality of life but also increases the burden of national medical expenses. It is known that isoflavones, especially isoflavone aglycones, are very effective among soy isoflavones in soybeans as a preventive measure for postmenopausal diseases that are of social interest (Masayoshi Yamaguchi, 2006, Yakugaku Zasshi, 126 (11) 1117-). 1137,) . Soybean is a high quality vegetable protein source and has been widely used for the production of tofu. Recently, as isoflavones are reported among various functional and physiologically active substances contained in soybean, it has been widely used as a material for functional health foods. DC et al, 1996, Obest. Gynecol, 87, 897-904).
따라서 본 발명은 비지에 미생물 Lactobacillus acidophilus 등을 이용하여 제조된 비지 발효물이 갱년기 여성 비만방지에 효과가 있다는 것을 확인하여 본 발명을 완성하였다．Therefore, the present invention has completed the present invention by confirming that the fermented fermented product prepared using Bigie microorganism Lactobacillus acidophilus and the like is effective in preventing menopausal women obesity.
따라서 본 발명의 목적은 두부 제조나 콩 가공 후 남아 버리는 찌꺼기인 비지에서 갱년기 여성 장애로 나타나는 비만 등에 효능이 있는 비지 발효물을 제공하는 것이다．Therefore, an object of the present invention is to provide a fermented fermented product which is effective in treating obesity, such as obesity, which appears as a menopausal disorder in women's bean curd, which is left behind after manufacturing tofu or processing soybeans.
상기의 목적을 달성하기 위하여 본 발명은 The present invention to achieve the above object
비지를 젖산 발효시켜 제조된 젖산 발효 산물을 주성분으로 하는 갱년기 여성 비만 억제용 조성물을 제공한다.Provided is a composition for inhibiting menopausal women's obesity, the main component of the lactic acid fermentation product produced by lactic acid fermentation.
본 발명의 일 실시예에 있어서, 상기 젖산 발효균은 Lactobacillus 속에 속하는 것이 바람직하고, 상기 젖산 발효균은 Lactobacillus acidophillus， 또는 또는 Lactobacillus brevis인 것이 더욱 바람직하며, Lactobacillus acidophillus가 가장 바람직하나 이에 한정되지 아니한다.In one embodiment of the present invention, the lactic acid fermentation bacteria are preferably belonging to the genus Lactobacillus, the lactic acid fermentation bacteria is more preferably Lactobacillus acidophillus, or Lactobacillus brevis, Lactobacillus acidophillus is most preferred, but is not limited thereto.
본 발명의 일 실시예에 있어서, 상기 조성물은 복부지방 감소에 효과가 있는 것을 특징으로 한다.In one embodiment of the present invention, the composition is characterized in that it is effective in reducing abdominal fat.
본 발명은 또한 비지를 젖산 발효시켜 제조된 젖산 발효 산물을 주성분으로 하는 갱년기 여성 고지혈증 예방 또는 치료용 조성물을 제공한다.The present invention also provides a composition for preventing or treating menopausal women's hyperlipidemia, the main component of which is a lactic acid fermentation product prepared by lactic acid fermentation.
본 발명의 일 실시예에 있어서, 상기 젖산 발효균은 Lactobacillus 속에 속하는 것이 바람직하고, 상기 젖산 발효균은 Lactobacillus acidophillus， 또는 Lactobacillus brevis인 것이 더욱 바람직하며, Lactobacillus acidophillus가 가 장 바람직하나 이에 한정되지 아니한다.In one embodiment of the present invention, the lactic acid fermentation bacteria is preferably belong to the genus Lactobacillus, the lactic acid fermentation bacteria is more preferably Lactobacillus acidophillus, or Lactobacillus brevis, Lactobacillus acidophillus is the most preferred, but is not limited thereto.
또 본 발명은 비지를 젖산 발효시켜 제조된 젖산 발효 산물을 주성분으로 하는 갱년기 여성 고콜레스테롤증 예방 또는 치료용 조성물을 제공한다.The present invention also provides a composition for preventing or treating menopausal women's hypercholesterolemia, the main component of which is lactic acid fermentation product prepared by lactic acid fermentation.
본 발명의 일 실시예에 있어서, 상기 젖산 발효균은 Lactobacillus 속에 속하는 것이 바람직하고, 상기 젖산 발효균은 Lactobacillus acidophillus， 또는 Lactobacillus brevis인 것이 더욱 바람직하며, Lactobacillus acidophillus가 가장 바람직하나 이에 한정되지 아니한다.In one embodiment of the present invention, the lactic acid fermentation bacteria are preferably belonging to the genus Lactobacillus, the lactic acid fermentation bacteria is more preferably Lactobacillus acidophillus, or Lactobacillus brevis, Lactobacillus acidophillus is most preferred, but is not limited thereto.
또 본 발명은 비지를 젖산 발효시켜 제조된 비지 젖산 발효 산물을 주성분으로 하는 갱년기 여성 골다공증 예방 또는 치료용 조성물을 제공한다.In another aspect, the present invention provides a composition for preventing or treating menopausal female osteoporosis, the main component of the non-lactic acid fermentation product produced by lactic acid fermentation.
본 발명의 일 실시예에 있어서, 상기 젖산 발효균은 Lactobacillus 속에 속하는 것이 바람직하고, 상기 젖산 발효균은 Lactobacillus acidophillus， 또는 Lactobacillus brevis인 것이 더욱 바람직하며, Lactobacillus acidophillus가 가장 바람직하나 이에 한정되지 아니한다.In one embodiment of the present invention, the lactic acid fermentation bacteria are preferably belonging to the genus Lactobacillus, the lactic acid fermentation bacteria is more preferably Lactobacillus acidophillus, or Lactobacillus brevis, Lactobacillus acidophillus is most preferred, but is not limited thereto.
이하, 본 발명을 설명한다.Hereinafter, the present invention will be described.
본 발명은 Lactobacillus Acidophillus 등을 이용해 비지를 발효시킴으로써 종전에 사용해 온 두유로부터 이소플라본 아글리콘을 추출해 얻은 양보다 약 ５배가 많은 양을 두유 제조 후 폐기되는 비지로부터 이소플라본을 대량 추출 제조하는 방법에 관한 것이다．The present invention is a method for producing a large amount of isoflavones from the waste paper, which is about 5 times more than the amount obtained by extracting the isoflavone aglycone from the soymilk that has been used before, by fermenting the soybean with Lactobacillus Acidophillus and the like. will be.
콩 １0 kg으로부터 나오는 비지는 １．２kg정도이며 전두유는 ７．８kg정도의 수율이다． 콩에서 두유를 분리한 후 비지에는 여러 가지 기능성 성분이 함유되어 있는 것으로 특히 비지에는 이소플라본 아글리콘 함량이 약 １７．８mg％로 비지 발효물에는 ３８．０mg％에 비해 낮은 함량을 차지하고 있는 것으로 나타나 있다． 따라서 지금까지는 두유를 이용해 이소플라본을 추출해 오고 있지만 본 발명은 두유 제조 후 폐기되는 비지에 Lactobacillus acidophilus로 발효 시킨 발효물에서 비지의 이소플라본 아글리콘보다 약 ２배 이상의 이소플라본 아글리콘을 함유하고 있는 조성물로 갱년기 여성 비만 방지 효과 등에 적용한 발명이다． Soybeans from soybeans weighing about 1,2 kg and soybean milk are about 7 kg. After soybean milk is separated from soybeans, the bean contains various functional ingredients.In particular, the bean contains about 107 mg of isoflavone aglycone, which is lower than that of the fermented fermented product, which is lower than that of 3.7 mg. have. Thus, until now, soymilk has been used to extract isoflavones, but the present invention is more than two times more oily than the isoflavone aglycone, which is about 2 times more than the isoflavone aglycone from the fermentation of fermented with Lactobacillus acidophilus. It is an invention applied to the effects of women's menopausal prevention of obesity.
본 발명은 두부 제조 후 폐기되는 비지에 Lactobacillus acidophilus를 접종해 발효시킴으로써 갱년기 여성 비만억제, 고지혈증 예방 등에 매우 효과가 우수한 조성물을 개발하였다.The present invention developed a composition having a very effective effect of inoculating menopausal women to suppress obesity, prevent hyperlipidemia, etc. by inoculating and fermenting Lactobacillus acidophilus to waste which is discarded after manufacturing tofu.
이하, 비한정적인 실시예를 통하여 본 발명을 더욱 상세하게 설명한다.Hereinafter, the present invention will be described in more detail with reference to non-limiting examples.
실시예Example : 미생물을 이용한 비지 발효 : Busy fermentation using microorganism
균주는 Lactobacillus acidophillus(ATCC 4356)를 사용하였다. MRS배지에서 37℃ 20시간 동안 3배수로 배양하였고 멸균된 비지 250 ml에 활성화 시킨 균주를 5 %(v/v) 접종하여 37 ℃에서 48시간 동안 발효시켰다. Lactobacillus acidophillus (ATCC 4356) was used as a strain. The cells were incubated in MRS medium for 3 hours at 37 ° C. for 20 hours and inoculated with 5% (v / v) of the activated strains in 250 ml of sterilized biji fermented at 37 ° C. for 48 hours.
실험예Experimental Example : : 비지발효물을Non fermentation 이용한 난소절제 동물에서의 비만 방지, 골다공증 및 고지혈증 실험 Obesity Prevention, Osteoporosis and Hyperlipidemia in Animals Using Ovarian Resection
(a) 시험동물은 SD（Sprague-Dawley) 계 암컷을 사용하였다． 시험 동물 구입은 일본（회사）5주령을 동물 입수해 ７일간 순화기간（온도２２±２℃， 상대습도 ５０±５％， 조명시간 １２시간， 조도 １５０～３００ Lux) 거친 후 난소를 적출하였다． 난소 적출 시킨 ７일후 군 분리하였다．(a) The test animals used Sprague-Dawley (SD) females. The animals purchased 5 weeks of age from Japan (Company) were subjected to a 7-day purifying period (temperature 2 ± 2 ℃, relative humidity of 55 ± 5%, lighting time of 12 hours, roughness of 1,500 to 300 Lux), and after that, the ovaries were removed. Seven days after ovarian extraction, the group was separated.
(b) 군의 구성은 다음과 같다． Normal Control, Sham Control, Ovariectomized Control(OC), OC+건조비지 추출물， OC+건조비지 발효물, OC+건조비지 발효 물 추출물 등 ６군으로 분리하였다．OC군은 전부 난소를 적출 한 군이다． 동물은 체중이 균등하도록 무작위법으로 한 군당 ８마리씩 분배하였다． (b) The composition of the group is as follows. It was divided into six groups: Normal Control, Sham Control, Ovariectomized Control (OC), OC + dry busy extract, OC + dry busy fermentation, OC + dry busy fermented product and extract. Animals were distributed in groups per group, randomly distributed so that the body weight was equal.
(c) 본 발명의 비지 발효물 시험물질의 투여는 일본에서 골다공증용 건조 사료를 기준으로 건조분말을 첨가해 투여물질로 사용하였으며， 증류수 및 액체 추출물은 경구 투여용 금속제 죤데를 이용해 ８주간 오전 １０시에 일정하게 위내에 강제로 투여하였다. (c) The administration of the test substance of the fermented fermented product of the present invention was used as a dosing material by adding a dry powder on the basis of a dry feed for osteoporosis in Japan, and the distilled water and liquid extracts were used for the use of metallurgy for oral administration. Xie was regularly forced into the stomach.
(d) 난소적출은 마취약（염산 케타민 ５０mg/ml, 유한양행＋xylazine 20mg/ml, 바이엘（주））을 시험동물에 근육주사하여 전신 마취 시킨 후 하복부의 털을 제거하고 요오드로 수술 부위를 소독 한 후， 난소를 적출하였다．(d) Ovarian extraction was performed by intramuscular injection of anesthetic drug (Ketamine hydrochloride (50mg / ml), Yuhan Corporation + xylazine 20mg / ml, Bayer Co., Ltd.) into the test animal to remove the body of the lower abdomen, and then remove the surgical site with iodine. Later, the ovary was removed.
(e) 투여기간 동안 시험동물에 대해 매주 １회씩（오전 １０시） 체중을 측정하고 사료 소비량을 측정하였다．(e) During the administration period, the body weight of the test animals was measured once a week (10:00 am) and the feed consumption was measured.
(f) 시험기간 종료 후 에테르 마취하에 하복부를 개복한 후 복대정 맥에서 채혈한 후， 각종 장기무게를 측정하고 대퇴골를 채취하였다．(f) After the end of the test period, the patient underwent ether anesthesia, and after the lower abdomen, the blood was collected from the abdominal vena cava.
(g) 채혈 한 혈액은 혈장을 분리하여 혈액학적 분석을 실시하였다． 혈액학적 검사는 WBC(（white blood cell), RBC(red blood cell), HGB(hemoglobin), HCT(hematocrit), MCHC(mean corpuscular hemoglobin concentration), MCH(mean corpuscular hemoglobin), MCV(mean corpuscular volume), PLT(platlet)를 혈구 분석기（Coulter counter(Coulter Co., Miami, FL., U.S.A)를 이용하여 측정하였다． 혈액 생화학 수치는 생화학 분석기를 이용하여 TG(Triglyceride), Total cholesterol, HDL-cholesterol(High density lipoprotein), LDL-cholesterol(Low density lipoprotein), ALP(Alkaline phosphatase), BUN, GOT(Glutamate oxaloacetic transferase), GPT(Glutamate Pyruvate transferase), P, Ca, K등을 각 측정하였다． 에스트라디올 측정은 radioimmunoassay법을 이용하였다． 복부 지방 측정은 복벽지방과 하복부 지방을 분리하여 분리해 측정용 저울（Mettler, PM 2000)로 측정하였다．(g) The collected blood was analyzed for hematological analysis by separating the plasma. Hematological tests include white blood cells (WBC), red blood cells (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), and mean corpuscular volume (MCV). PLT (platlet) was measured using a blood cell analyzer (Coulter counter (Coulter Co., Miami, FL., USA)). Blood biochemistry values were measured using biochemistry analyzers, including triglyceride (TG), total cholesterol, HDL-cholesterol (high density lipoprotein), LDL-cholesterol (Low density lipoprotein), ALP (Alkaline phosphatase), BUN, GOT (glutamate oxaloacetic transferase), GPT (Glutamate Pyruvate Transferase), P, Ca and K were measured. Estradiol measurement was performed using the radioimmunoassay method. Abdominal fat measurements were determined by separating the abdominal wall fat and the lower abdominal fat and measuring them with a measuring scale (Mettler, PM 2000).
상기의 실험예를 통한 결과는 다음과 같다.The results through the above experimental example are as follows.
1. 본 발명에 사용 된 난소 적출군은 정상 대조군에 비해 체중이 유의성 있게 증가하였으며， 비지 발효물 투여군은 비비 투여군과 난소 적출 대조군에 비해 체중이 유의하게 감소되었다． 난소 적출군 모두 자궁 위축 현상이 관찰 되었다(도 2 참조). 1. Ovarian extraction group used in the present invention significantly increased the body weight compared to the normal control group, the non-fermented fermentation group was significantly reduced in weight compared to the non-administration group and ovary extraction control group. Uterine atrophy was observed in all ovarian extraction groups (see FIG. 2).
2. 장기 무게 측정 결과는 도 2에 나타내었다． 해부 결과 정상 대조군 및 Sham군에 비해 난소 적출군 모두 자궁 위축 현상이 관찰 되었 다． 그러나 비지 발효물 투여군에서는 비지 투여군， 난소적출 대조군 및 비지 발효 추출물 군에 비해 자궁위축 정도가 현저히 감소되었다．2. The long-term weight measurement results are shown in Figure 2. As a result of the dissection, ovarian atrophy was observed compared to normal control and Sham. However, the degree of uterine atrophy was significantly reduced in the busy fermentation group compared to the busy administration group, ovarian extraction control group and the busy fermentation extract group.
3. 혈액 생화학적 측정 결과는 표(도 3 참조)에서 나타내었다． 비지 발효물 투여군이 비지 투여군 및 난소절제 대조군에 비해 TG(Triglyceride), Total cholesterol 및 LDL-cholesterol(Low density lipoprotein)이 유의하게 감소하는 결과를 보였다．3. The results of blood and biochemical measurements are shown in Table (see Fig. 3). Triglyceride (TG), total cholesterol, and LDL-cholesterol (Low density lipoprotein) significantly decreased compared with the control group of the business.
4. 에스트라디올 농도는 난소 적출 시 감소하는 경향을 나타내었다． 비지 발효물 투여군이 비지 투여군 및 난소절제 대조군에 비해 에스트라디올 농도가 유의하게 증가하였다．(도 4 참조) 4. Estradiol concentration showed a tendency to decrease when the ovaries were removed. In comparison with the fermentation group and the ovarian ablation control group, the fermentation product of the busy fermented product significantly increased the concentration of estradiol (see Fig. 4).
5. 복부지방 측정 결과는 도 5에 나타내었다．5. Abdominal fat measurement results are shown in Figure 5.
복부 지방은 난소 적출군에 정상 대조군 및 Sham 대조군에 비해 유의하게 증가하였다． 그러나， 비지 발효물 투여군은 비지 투여군 및 난소 절제 대조군에 비해 복부지방이 유의하게 감소하였다．Abdominal fat increased significantly in ovarian extraction compared with normal control and Sham control. However, the abdominal fat decreased significantly compared to the busy administration and ovariectomy control groups.
6. 골다공증에 대한 측정 결과는 도 6에 나타내었다.6. Measurement results for osteoporosis are shown in FIG.
도 6에서 알 수 있는 바와 같이, 대퇴골에서 골다공증 및 골재생 여부를 판독하기 위하여 뼈잔기둥의 형성(formation of trabecular bone), 골수내 지방축적(fatty accumulation) 및 뼈파괴세포의 증감여부(numbers of osteoclasts)를 주요 조직병리학적 소견으로 선정하여 각 검체를 비교하였다. 골다공증은 뼈잔기둥의 두께 및 수적 감소, 골수 내 지방축적 및 파골세포의 증가가 두드러진 소견으로 뼈잔기둥의 소실 및 굵기 감소는 골다공증의 정도를 가장 명확하게 반영하는 지표가 될 수 있다. 본 시험에서는 뼈잔기둥의 형성이 현저하고 지방축적 및 파골세포의 수가 적을수록 시험물질이 효과가 있는 것으로 판단하였다. 병변의 정도는 각 항목별로 소견이 가장 심한 경우를 3+로 하였으며, 시험과 관련된 병변 중에서 그 정도가 가장 극미한 경우를 ±로 평가하였다. 이와 같은 기준에 따라 병변의 정도는 모두 4등급으로 나누어 상대적인 평가를 수행하였다. As can be seen in Figure 6, the formation of trabecular bone, fat accumulation in bone marrow (numbers of osteoclasts) to determine whether osteoporosis and bone regeneration in the femur ) Were selected as the major histopathological findings. Osteoporosis is characterized by a decrease in thickness and number of bone pillars, fat accumulation in bone marrow, and an increase in osteoclasts. The loss and thickness of bone pillars can be the most significant indicator of the degree of osteoporosis. In this study, it was judged that the test substance was more effective as the formation of the columnar bone was outstanding and the fat accumulation and the number of osteoclasts were small. The degree of lesion was 3+ for the most severe findings of each item. According to these criteria, the extent of lesions was divided into 4 grades for relative evaluation.
검체 중에서 NC군, SC군 및 FSP군에 속하는 검체에서는 뼈잔기둥의 형성이 현저한 반면, 지방축적의 정도 및 파골세포의 수는 경도로 확인되어 본 시험에서 병변이 가장 적은 것으로 판단되었다. In the specimens belonging to NC, SC, and FSP groups, bone streak formation was remarkable, whereas fat accumulation and number of osteoclasts were found to be mild.
따라서 본 시험에서 병변이 가장 적게 관찰된 군은 NC군으로 확인되었으며, 가장 심한 군은 뼈잔기둥의 형성이 경도이며, 지방축적 및 파골세포의 수가 중등도에서 심한 정도를 보인 Con군인 것으로 확인되었다. In this study, the least lesions were found in the NC group, and the most severe group was the Con group with mild to severe bone formation and moderate to severe accumulation of fat accumulation and osteoclasts.
도 1은 본 발명에 따라 나타난 난소 적출시술 후 비지 발효물의 투여 시험기간 동안의 시험에 사용된 동물에 대한 매주 일정시간 １회 체중을측정한 결과를 나타낸 체중 및 사료효율을 나타내었다． Figure 1 shows the weight and feed efficiency of the results of the measurement of the weight of the week once a week for the animals used for the test during the administration of the fermentation of the busy fermentation after the ovarian extraction procedure according to the present invention.
도 ２는 본 발명에 따라 난소 적출시술 후 비지 발효물의 투여 시험기간 동안의 시험에 사용된 동물의 시험 사육기간 종료 후의 복대정맥 채혈 후 간장， 신장， 비장， 심장， 폐， 자궁， 하복부 지방 및 복벽지방의 무게를 저울로 측정한 결과를 나타내었다．Fig. 2 shows the hepatic, kidney, spleen, heart, lung, lung, uterine wall, and abdominal abdominal fat after the ovarian extraction procedure and the administration of the fermentation of the busy fermentation during the test period. The results of measuring the weight of the fat with a scale are shown.
도 3은 본 발명에 따라 나타난 생화학분석기를 사용해 Total cholesterol,HDL-cholesterol, HDL, LDL-cholesterol를 측정한 결과를 나타낸다. 본 결과는 난소 적출된 쥐를 7일간 본 발명의 물질을 먹인 후 측정한 결과이다.Figure 3 shows the result of measuring the total cholesterol, HDL-cholesterol, HDL, LDL-cholesterol using the "biochemical analyzer" according to the present invention. This result is the result of measuring the ovarian isolated rats after feeding the substance of the present invention for 7 days.
도 4는 본 발명에 따라 Estradiol측정을 radioimmunoassay법을 이용해 측정한 결과를 나타낸 것이다． Fig. 4 shows the result of measuring the Estradiol measurement using the radioimmunoassay method according to the present invention.
도 5는 본 발명에 따라 복부지방의 무게를 측정한 것으로 하복부 지방 및 복벽지방을 구별해 측정용 저울（Mettler, PM 2000) 로 측정한 결과를 나타낸 것이다．5 is a measurement of the weight of the abdominal fat according to the present invention shows the results of the measurement by measuring the measurement scale (Mettler, PM 2000) by distinguishing the lower abdominal fat and abdominal wall fat.
도 6은 본 발명에 따라 랫트 대퇴골의 조직병리학적 데이터를 통한 본 발명의 골다공증 치료 및 예방과 관련된 데이터이다.Figure 6 is data related to the treatment and prevention of osteoporosis of the present invention through histopathological data of rat femur according to the present invention.
Claims (11)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080013606A KR20090088205A (en) | 2008-02-14 | 2008-02-14 | Composition of biji fermentation products with lactobacillus acidophillus on the prevention of menopausal obesity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080013606A KR20090088205A (en) | 2008-02-14 | 2008-02-14 | Composition of biji fermentation products with lactobacillus acidophillus on the prevention of menopausal obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20090088205A true KR20090088205A (en) | 2009-08-19 |
Family
ID=41206962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020080013606A KR20090088205A (en) | 2008-02-14 | 2008-02-14 | Composition of biji fermentation products with lactobacillus acidophillus on the prevention of menopausal obesity |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20090088205A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101493954B1 (en) * | 2013-05-23 | 2015-02-17 | 명지대학교 산학협력단 | Multifunctional soybean byproducts fermented with Aspergillus species, method for preparing the same and use of the same |
| KR20180018422A (en) * | 2016-08-12 | 2018-02-21 | 한국식품연구원 | Composition for preventing or treating of climacterium comprising Lactobacillus acidophilus |
| KR20200136721A (en) | 2019-05-28 | 2020-12-08 | 동아제약 주식회사 | Composition for preventing or treating woman menopause symptoms comprising Cordyceps militaris Concentrate as an active ingredient |
| WO2020231029A3 (en) * | 2019-05-14 | 2021-03-11 | 한국식품연구원 | Composition for preventing, alleviating or treating hot flashes, tingling of limbs or palpitation in menopausal women, containing lactobacillus acidophilus |
-
2008
- 2008-02-14 KR KR1020080013606A patent/KR20090088205A/en not_active Application Discontinuation
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101493954B1 (en) * | 2013-05-23 | 2015-02-17 | 명지대학교 산학협력단 | Multifunctional soybean byproducts fermented with Aspergillus species, method for preparing the same and use of the same |
| KR20180018422A (en) * | 2016-08-12 | 2018-02-21 | 한국식품연구원 | Composition for preventing or treating of climacterium comprising Lactobacillus acidophilus |
| JP2019524138A (en) * | 2016-08-12 | 2019-09-05 | コリア フード リサーチ インスティテュート | A composition for preventing or treating menopause, comprising Lactobacillus acidophilus |
| EP3498821A4 (en) * | 2016-08-12 | 2020-04-01 | Korea Food Research Institute | Composition for preventing or treating menopause, containing lactobacillus acidophilus |
| US11260087B2 (en) | 2016-08-12 | 2022-03-01 | Korea Food Research Institute | Composition for preventing or treating menopause, containing Lactobacillus acidophilus |
| WO2020231029A3 (en) * | 2019-05-14 | 2021-03-11 | 한국식품연구원 | Composition for preventing, alleviating or treating hot flashes, tingling of limbs or palpitation in menopausal women, containing lactobacillus acidophilus |
| KR20200136721A (en) | 2019-05-28 | 2020-12-08 | 동아제약 주식회사 | Composition for preventing or treating woman menopause symptoms comprising Cordyceps militaris Concentrate as an active ingredient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2474237B1 (en) | Equol-containing fermentation product of soybean embryonic axis, and method for production thereof | |
| KR101252639B1 (en) | Composition for Prevention or Treatment of Osteoporosis Comprising Ssanghwatang and Fermentation Product Thereof with Lactic Acid Bacteria | |
| US20110052644A1 (en) | Composition comprising extract of cinnamomum cassia bark for improving normal flora and enhancing immune response | |
| KR20160041138A (en) | Composition for Prevention or Treatment of Obesity Comprising Tenebrio molitor larva extract or Tenebrio molitor larva suspension | |
| KR20090088205A (en) | Composition of biji fermentation products with lactobacillus acidophillus on the prevention of menopausal obesity | |
| JP2022522727A (en) | A composition for the prevention, amelioration or treatment of obesity or fatty liver disease containing Weissella Helenica WIKIM0103. | |
| Sengupta et al. | Hypolipidemic effects of soy yogurt fortified with antioxidant rich vegetable oil on albino mice fed high cholesterol diet | |
| KR102159447B1 (en) | Composition for preventing and treating of bone diseases comprising fermented extracts from aronia and black rice | |
| KR101402926B1 (en) | Pharmaceutical composition and functional food for prevention or treatment of bone disease comprising the lactic acid bacteria ferment of hwangryunhaedoktang | |
| Motawee | Biological effects of yoghurt with rosemary on injured liver rats | |
| JP2007291081A (en) | Composition having bone resorption inhibition-related effect | |
| Kan et al. | In vitro antiviral activities under cytotoxic doses against herpes simples type-1 and parainfluensa-3 viruses of Cicer arietinum L.(Chickpea) | |
| Tao et al. | Genotoxicity, acute and subchronic toxicity evaluation of fermented Morinda officinalis | |
| WO2009057954A2 (en) | Composition for improvement of fatty liver | |
| KR101729827B1 (en) | Garlic stem powder and tablet manufacturing method using thereof | |
| KR20060115383A (en) | Composition for preventing and treating hepatoma | |
| JP2009096719A (en) | Osteoclast differentiation inhibitor | |
| KR100832520B1 (en) | A composition for the treatment or prevention of osteoporosis comprising an extract of capsosiphon fulvecense | |
| KR20130143330A (en) | Composition containing fermented rice bran for the prevention and treatment of non-alcoholic fatty liver | |
| CN112708652B (en) | Avocado oil-in-water liquid state fermentation product and preparation method and application thereof | |
| TW202403039A (en) | Lactobacillus johnsonii and uses of lactobacillus johnsonii or it's metabolite for increasing the degree of unsaturation in fatty acid | |
| KR20180088947A (en) | Manufacturing method of lotus leaf fermented extract, meat producing stuff having anti-obesity functional using the fermented extract anc meat product thereby | |
| KR101097838B1 (en) | A method for preparing fermented soymilk having improved good sensory property and Lipid lowering ability by Bacillus subtilis and Corni fructus, and fermented soymilk for prevention atherosclerosis obtained from this method | |
| OI et al. | Effect of Sumac (Rhus Coriaria L.) Herbal on Induced Osteoporosis in Female Rats | |
| KR101771077B1 (en) | Composition for improving hematogenous functions and preventing anemia comprising extracts of fermented Arctium lappa L.and Spinacia oleracea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E90F | Notification of reason for final refusal | ||
| E601 | Decision to refuse application |